Bionorica   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Neumarkt Germany (1933)
Status: No NME R&D (1933)

Organization Overview

First Clinical Trial
2007
NCT00959218
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Bionorica Research GmbH | Bionorica SE

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 3)

Disease (Phase 2)

Infections (Phase 3)

Mastodynia (Phase 3)

Multiple Sclerosis (Phase 3)

Muscle Spasticity (Phase 3)

Nausea (Phase 3)

Neuralgia (Phase 3)

Pancreatic Neoplasms (Phase 3)

Premenstrual Syndrome (Phase 3)

Sclerosis (Phase 3)

Sinusitis (Phase 3)

Stress Disorders, Post-Traumatic (Phase 2)

Stress Disorders, Traumatic (Phase 2)

Syndrome (Phase 3)

Urinary Tract Infections (Phase 3)

Vomiting (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial APIs: 15